Burden and management of gout in a multi-ethnic Asian cohort

Rheumatol Int. 2020 Jul;40(7):1029-1035. doi: 10.1007/s00296-019-04475-6. Epub 2019 Nov 22.

Abstract

Gout has significant impact on the quality of life with over-utilisation of health resources. While lowering serum urate (SU) to ≤ 360 µmol/L improves clinical outcomes, this is usually not achieved. We describe the burden of gout and determine predictors of achieving SU target in gout patients in Singapore. This was a cross-sectional study of 282 gout patients from a Singapore hospital rheumatology service. Sociodemographic and lifestyle factors, co-existing medical conditions and medications, gout history and severity, SU levels and treatment were obtained. Patients with SU ≤ 360 µmol/L were compared with those > 360 µmol/L to determine factors associated with achieving SU target. Descriptive statistics and multivariate model were used. Severe disease was reported in 50%, with emergency attendances and hospitalisations in 33% and 19% respectively, and unemployment in 32%. Only 22% were at SU target and 67% on urate-lowering therapy (ULT) at recruitment. Hypertension, dyslipidaemia, chronic kidney disease and diabetes were prevalent in 56.7%, 48.2%, 32.3% and 18.8%, respectively. Malays had more comorbidities compared to Chinese participants. In multivariate analysis, ULT prescription and ≥ 2 comorbidities were associated with reaching SU target with odds ratios of 3.92 [95% confidence interval (CI) (1.75-8.71)] and 2.65 [95% CI (1.59-4.43)] respectively, independent of age, tophi, disease duration, body mass index, alcohol and diuretic use. Patients with gout have high disease burden resulting in significant healthcare utilisation. SU control is sub-optimal hence the use of ULT remains key in achieving SU target. Patients with other comorbidities are more likely to reach target than those with only gout as a single diagnosis.

Keywords: Burden; Comorbidity; Gout; Healthcare utilisation.

MeSH terms

  • Adult
  • Aged
  • Allopurinol / therapeutic use
  • Comorbidity
  • Cross-Sectional Studies
  • Diabetes Mellitus / epidemiology
  • Dyslipidemias / epidemiology
  • Emergency Service, Hospital / statistics & numerical data
  • Ethnicity
  • Febuxostat / therapeutic use
  • Female
  • Gout / blood
  • Gout / drug therapy
  • Gout / epidemiology*
  • Gout / physiopathology
  • Gout Suppressants / therapeutic use*
  • Hospitalization / statistics & numerical data
  • Humans
  • Hypertension / epidemiology
  • Hyperuricemia / blood
  • Hyperuricemia / drug therapy
  • Hyperuricemia / epidemiology*
  • Hyperuricemia / physiopathology
  • Male
  • Middle Aged
  • Probenecid / therapeutic use
  • Renal Insufficiency, Chronic / epidemiology
  • Severity of Illness Index
  • Singapore / epidemiology
  • Treatment Outcome
  • Uric Acid / blood*

Substances

  • Gout Suppressants
  • Febuxostat
  • Uric Acid
  • Allopurinol
  • Probenecid